Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer
Condition: HER2-negative Breast Cancer Interventions: Biological: Tislelizumab; Drug: Nab paclitaxel; Drug: Doxorubicin; Drug: Epirubicin; Device: Cyclophosphamide Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences; First Affiliated Hospital Xi'an Jiaotong University; Wuhan Union Hospital, China; Beijing Huanxing Cancer Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Academies | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | China Health | HER2 | Hospitals | Research | Study